CWRP
ADMA icon

Cassady Wealth & Retirement Planning’s ADMA Biologics ADMA Stock Holding History

Cassady Wealth & Retirement Planning’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.9K Buy
10,026
+26
+0.3% +$237 0.04% 104
2026
Q1 		$103K Hold
10,000
– – 0.05% 101
2025
Q4 		$182K Buy
+10,000
New +$169K 0.12% 97

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Cassady Wealth & Retirement Planning's ADMA Position: Q2 2026 in Review

Cassady Wealth & Retirement Planning increased its ADMA Biologics (ADMA) stake by 0.26% in Q2 2026, buying an estimated $237 and bringing the position to 10,026 shares worth $83.9K. The position accounts for 0.04% of the portfolio, ranked #104.

Cassady Wealth & Retirement Planning first reported a position in ADMA in Q4 2025 and has held it in 3 quarters since. The position peaked at $182K in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Cassady Wealth & Retirement Planning held 10,026 shares of ADMA Biologics worth $83.9K as of Q2 2026.
  • Cassady Wealth & Retirement Planning bought 26 ADMA Biologics shares in Q2 2026, an estimated $237.
  • ADMA Biologics made up 0.04% of Cassady Wealth & Retirement Planning's portfolio in Q2 2026, its #104 holding.
  • Cassady Wealth & Retirement Planning first reported a position in ADMA Biologics in Q4 2025 and has held it in 3 quarters since.
  • Cassady Wealth & Retirement Planning's ADMA Biologics position peaked at $182K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Cassady Wealth & Retirement Planning's 13F filing for Q2 2026, filed 27 Jul 2026.